Elevance Health, Inc. $ELV Stock Position Raised by Hyperion Capital Advisors LP

Hyperion Capital Advisors LP raised its stake in shares of Elevance Health, Inc. (NYSE:ELV) by 46.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 51,643 shares of the company’s stock after buying an additional 16,429 shares during the period. Elevance Health comprises approximately 8.9% of Hyperion Capital Advisors LP’s holdings, making the stock its 3rd largest position. Hyperion Capital Advisors LP’s holdings in Elevance Health were worth $16,687,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of ELV. Gotham Asset Management LLC increased its position in Elevance Health by 97.9% during the third quarter. Gotham Asset Management LLC now owns 117,407 shares of the company’s stock valued at $37,937,000 after acquiring an additional 58,077 shares during the last quarter. Focus Partners Wealth boosted its position in Elevance Health by 63.6% in the third quarter. Focus Partners Wealth now owns 36,718 shares of the company’s stock worth $11,864,000 after purchasing an additional 14,279 shares during the last quarter. Fort Point Capital Partners LLC grew its stake in shares of Elevance Health by 7.1% during the 3rd quarter. Fort Point Capital Partners LLC now owns 668 shares of the company’s stock valued at $216,000 after purchasing an additional 44 shares during the period. Distillate Capital Partners LLC increased its position in shares of Elevance Health by 31.9% during the 3rd quarter. Distillate Capital Partners LLC now owns 76,502 shares of the company’s stock valued at $24,730,000 after purchasing an additional 18,508 shares during the last quarter. Finally, Eminence Capital LP increased its position in shares of Elevance Health by 52.1% during the 3rd quarter. Eminence Capital LP now owns 366,789 shares of the company’s stock valued at $118,517,000 after purchasing an additional 125,632 shares during the last quarter. 89.24% of the stock is owned by institutional investors.

Elevance Health Price Performance

NYSE ELV opened at $291.69 on Monday. The company has a current ratio of 1.54, a quick ratio of 1.54 and a debt-to-equity ratio of 0.70. Elevance Health, Inc. has a 12 month low of $273.71 and a 12 month high of $458.75. The stock has a market cap of $64.38 billion, a price-to-earnings ratio of 11.61, a PEG ratio of 1.61 and a beta of 0.51. The company’s 50 day moving average is $338.25 and its two-hundred day moving average is $334.45.

Elevance Health (NYSE:ELV) last posted its quarterly earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share for the quarter, topping analysts’ consensus estimates of $3.10 by $0.23. The business had revenue of $49.31 billion during the quarter, compared to analyst estimates of $49.52 billion. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The company’s revenue was up 9.6% on a year-over-year basis. During the same period in the prior year, the business posted $3.84 earnings per share. Elevance Health has set its FY 2026 guidance at 25.500- EPS. As a group, research analysts anticipate that Elevance Health, Inc. will post 33.96 earnings per share for the current year.

Elevance Health Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th will be issued a $1.72 dividend. The ex-dividend date of this dividend is Tuesday, March 10th. This represents a $6.88 annualized dividend and a yield of 2.4%. This is an increase from Elevance Health’s previous quarterly dividend of $1.71. Elevance Health’s payout ratio is currently 27.39%.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on ELV. Barclays dropped their price objective on shares of Elevance Health from $404.00 to $393.00 and set an “overweight” rating on the stock in a report on Friday, January 30th. Guggenheim reduced their target price on shares of Elevance Health from $414.00 to $396.00 and set a “buy” rating for the company in a report on Thursday, January 29th. JPMorgan Chase & Co. increased their price target on shares of Elevance Health from $394.00 to $397.00 and gave the stock an “overweight” rating in a research report on Monday, February 2nd. Morgan Stanley cut their price objective on shares of Elevance Health from $359.00 to $352.00 and set an “equal weight” rating for the company in a research report on Wednesday, December 17th. Finally, Wall Street Zen lowered Elevance Health from a “buy” rating to a “hold” rating in a research note on Sunday, February 8th. Twelve investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Elevance Health has a consensus rating of “Moderate Buy” and an average price target of $387.40.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.